ESTRO 2025 - Abstract Book

S840

Clinical - Gynaecology

ESTRO 2025

2. Pötter R, Tanderup K, Kirisits C, et al.; EMBRACE Collaborative Group. The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies. Clin Transl Radiat Oncol. 2018 Jan 11;9:48-60. doi: 10.1016/j.ctro.2018.01.001. 3. EMBRACE II study protocol https://www.embracestudy.dk

2687

Poster Discussion Age-related differences in patient preferences for adjuvant chemotherapy for high-risk endometrial cancer Famke C. Wakkerman 1 , Cathalijne C. B. Post 1 , Jan Willem M. Mens 2 , Ina M. Jürgenliemk-Schulz 3 , Friederike L.A. Koppe 4 , Marie A.D. Haverkort 5 , Ellen M.A. Roeloffzen 6 , An Snyers 7 , Marianne A. A. de Jong 8 , Eva E. Schaake 9 , Jannet C. Beukema 10 , Jeltsje Cnossen 11 , Mandy Kiderlen 12 , Ludy C.H.W. Lutgens 13 , Hans W. Nijman 14 , Cornelis D. de Kroon 15 , Judith R. Kroep 16 , Arwen H. Pieterse 17 , Carien L. Creutzberg 1 , Nanda Horeweg 1 1 Department of Radiation Oncology, Leiden University Medical Center, Leiden, Netherlands. 2 Department of Radiotherapy, Erasmus MC Cancer Center, Rotterdam, Netherlands. 3 Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, Netherlands. 4 Department of Radiotherapy, Institute Verbeeten, Tilburg, Netherlands. 5 Department of Radiotherapy, Radiotherapiegroep, Arnhem, Netherlands. 6 Department of Radiation Oncology, Isala, Zwolle, Netherlands. 7 Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, Netherlands. 8 Department of Radiation Oncology, Radiotherapeutisch Instituut Friesland, Leeuwarden, Netherlands. 9 Department of Radiation Oncology, National Cancer Institute, Amsterdam, Netherlands. 10 Department of Radiation Oncology, University Medical Center Groningen, Groningen, Netherlands. 11 Department of Radiation Oncology, Catharina Hospital, Eindhoven, Netherlands. 12 Department of Radiation Oncology, Haaglanden Medical Center, The Hague, Netherlands. 13 Department of Radiation Oncology, Maastro, Maastricht, Netherlands. 14 Department of obstetrics and gynecology, University Medical Center Groningen, Groningen, Netherlands. 15 Department of obstetrics and gynecology, Leiden University Medical Center, Leiden, Netherlands. 16 Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands. 17 Department of biomedical data sciences, Leiden University Medical Center, Leiden, Netherlands Purpose/Objective: Adjuvant chemotherapy in the treatment of endometrial cancer can be difficult to tolerate for older women. Even when women are fit enough to endure chemotherapy, the acute side effects and long-term toxicity can impact their quality of life and day-to-day functioning. The aim of the current study was to investigate the preferences for chemotherapy in different age groups among women with high-risk endometrial cancer. Material/Methods: Data from a previous cross-sectional patient preference study, called PRETEC-2 [1], was re-analyzed to compare three clinically relevant age groups (<60 years, 60-69 years and ≥70 years). Patients with high-risk endometrial cancer treated with adjuvant pelvic radiotherapy with or without chemotherapy were enrolled across 12 radiation oncology centers in the Netherlands. Consenting patients were asked to complete a treatment trade-off questionnaire to assess their minimally desired five-year overall survival benefit from the addition of chemotherapy to pelvic radiotherapy. Furthermore, patients were asked to rate the importance of treatment-related side effects and deterioration in functioning, as identified in the PORTEC-3 trial [2]. Results: In total, 453 eligible patients were approached, of whom 205 responded to the questionnaire (response rate 45.3%). After excluding incomplete questionnaires, 171 patients (23% <60 years, 40% 60-69 years and 37% ≥70 years) were included for analysis. Older patients had a significantly higher median minimally desired survival benefit for chemotherapy compared to younger patients (5% for <60 years, 8% for 60-69 years and 15% for patients ≥70 years; (p<0.001)). Patients aged ≥70 years had the largest variability in minimally desired survival benefit (Figure 1). For a real-life five-year survival benefit of 5%, fewer older patients preferred addition of chemotherapy (61.5% for <60